LB002ILLUMINATE-A, A PHASE 3 STUDY OF LUMASIRAN, AN INVESTIGATIONAL RNAI THERAPEUTIC, IN CHILDREN AND ADULTS WITH PRIMARY HYPEROXALURIA TYPE 1 (PH1)
Sander F. Garrelfs(Emma Kinderziekenhuis), John C. Lieske(Mayo Clinic), Jiandong Lu(Guangzhou University of Chinese Medicine), William van’t Hoff(Great Ormond Street Hospital), David J. Sas(Mayo Clinic), Georges Deschênes(Hôpital Robert-Debré), Michael J. Koren(Jacksonville Center for Clinical Research), Gesa Schalk, Hadas Shasha‐Lavsky(Université Claude Bernard Lyon 1), John M. Gansner(Brigham and Women's Hospital), Pierre Cochat(Société Nationale des Chemins de Fer Français (France)), Daniel G. Fuster(University Hospital of Bern), Eva Šimková(Université Claude Bernard Lyon 1), Jeffrey M. Saland(Université Claude Bernard Lyon 1), Yaacov Frishberg(Shaare Zedek Medical Center), Pushkal Garg(Université Paris-Sud), Daniella Magen(Université Claude Bernard Lyon 1), Shabbir H. Moochhala(Université Claude Bernard Lyon 1), William O’Riordan(Université Paris-Sud), Sally A. Hulton(Birmingham Children's Hospital), Jaap W. Groothoff(University of Amsterdam), Tracy L. McGregor(Université Claude Bernard Lyon 1), Kristin Meliambro(Icahn School of Medicine at Mount Sinai)
Cited by 21
Related Papers
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
|New England Journal of Medicine|2015|1.5k
Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials
|The Lancet|2019|785
A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
|New England Journal of Medicine|2014|712
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1
|New England Journal of Medicine|2021|505